Inside OpenAI Enterprise: Forward Deployed Engineering, GPT-5, and More | BG2 Guest Interview

What It Covers

OpenAI's enterprise platform leaders discuss forward deployed engineering, GPT-5 development, real-time voice API, reinforcement fine-tuning, and major deployments at T-Mobile, Amgen, and Los Alamos National Labs transforming customer support, drug development, and national security research.

Key Questions Answered

• •Forward Deployed Engineering: OpenAI embeds engineers directly with enterprise customers like T-Mobile to build custom integrations, connect models to internal CRM systems without APIs, design evaluation frameworks, and optimize latency for production voice calls—moving beyond simple API access to full system implementation.
• •Reinforcement Fine-Tuning Advantage: RFT allows enterprises to create best-in-class models for specific domains using their own data and gradable tasks. Rogo achieved superior results on financial document parsing, while Accordance reached state-of-the-art performance on CPA-level tax tasks using OpenAI's RFT product.
• •GPT-5 Design Philosophy: Development prioritized customer feedback over benchmark saturation, focusing on instruction following precision, reduced hallucinations approaching zero, code quality improvements, and behavior tuning. Months of embedded customer work shaped the model's tone, style, and practical business application capabilities beyond raw intelligence.
• •Real-Time Voice API Architecture: Speech-to-speech models eliminate the three-step pipeline of speech-to-text, reasoning, and text-to-speech. This preserves emotional signals, accents, and tone while reducing latency and interruptions. T-Mobile deployed this for automated customer support calls requiring natural human-sounding interactions at scale.
• •Healthcare AI Acceleration: Pharmaceutical companies like Amgen represent the highest-potential AI transformation sector due to massive structured data volumes, document-heavy regulatory processes, and technical R&D culture. Automating drug approval documentation and research analysis could double medication development rates, impacting hundreds of millions of lives.